Try our Advanced Search for more refined results
Life Sciences - December, 2018
222 articles
- 5 Most-Read Legal Industry Guests Of 2018
- Top 5 International Tax Cases Of 2018
- 3rd Circ. Questions Legal Standard In Foreign Account Case
- Atty's Widow Asks High Court To Look At Case Against GSK
- CVS Unit's Doubled $1.3M FCRA Deal 'Odd,' Judge Says
- Stericycle Reaches $45M Settlement In Securities Suit
- FDA Tells Stem Cell Cos. Regulatory Eyes Fixed On Them
- Join Suits Over HIV Drugs In Calif., Patients Urge JPML
- Takeda's Patent Infringement Suit Not Antitrust-Proof
- Purdue Says Texas Can't Slip Out From Opioid MDL
- Latham Leads Firms In IPO Deals After Market's Robust Year
- Dental Supply Co. Was In On Price-Fixing, Investors Say
- Pair Overdose Antidote With Opioid Prescriptions, HHS Urges
- 2018 Farm Bill Marks Watershed Moment For Industrial Hemp
- Caribbean Court Sides With Sinovac In Board Dispute
- J&J Can't Shake Miss. AG's Suit Alleging Talc Dangers
- House Tees Off Vote For Revised Tax Bill, But Fate Uncertain
- Ohio Opioid MDL Bellwether Survives Drug Co. Attacks
- J&J Can't Shed $4.7B Talc Verdict In Missouri
- Aralez Ch. 11 Inches Forward With 'Weird' Sale Proposal
- Relators Double Down In Gilead FCA Case After DOJ Threat
- Fresenius Gets Win In Suit Over Hospira Sedative Patents
- Generic-Drug Cos. Want AGs To Shut Up About Price-Fixing
- Judge Finds NY's $600M Opioid Surcharge Unconstitutional
- SF Becomes Latest To Sue Pharma Cos. Over Opioid Crisis
- Cocaine Anesthetic Not FDA-Approved, Rival Drugmaker Says
- UK Looks Harder At Thermo Fisher $925M Microscope Deal
- Talc Miner Released From Fla. Product Liability Suit
- Verrill Dana Adds Health Care, Privacy Expert In Boston
- NJ High Court To Review Merck Shareholder's Doc Request
- 5 Firms Rep GSK, Pfizer In £9.8B Consumer Health Biz Merger
- Ballard Spahr Nabs IP Partner From McCarter & English
- New Hatch-Waxman Integrity Act Brings Hope For Patients
- 3 Firms Guide Bristol-Myers On $1.6B Offer For French Unit
- Questions Follow 9th Circ. Solidification Of Escobar Test
- Ariz. High Court Rejects 9th Circ. Preemption Ruling
- EpiPen MDL Gets Special Master To Deal With Disputed Docs
- DOJ Aims Torpedo At 11 FCA Kickback Suits
- Celgene Wants Mylan Sanctioned For Bid To Add Witnesses
- Where 5 Top MDLs Stand At The End Of 2018
- Sen. Warren Wants HHS To Make, Sell Generic Drugs
- DC Circ. Won't Rehear Med Tech Co.'s $400M Award Denial
- Medtronic, Ex-PTAB Chief Settle Gay Discrimination Suit
- Proskauer Steers $184M RiverVest Life Science-Focused Fund
- $2.4M Settlement Reached In J&J 'Natural' Baby Wash Suit
- The State Of Pharma Class Certification After Asacol
- The Moments That Mattered Most For Legal Ethics In 2018
- How Product Liability Law Works In Denmark
- Both Sides In Insys Case Violated Media Rules, Judge Says
- Insights On Right To Try Act And 'Expanded Access' Concerns
- The Year #MeToo Rocked In-House Law Departments
- Sens. Appear Keen On Drafting New Patent Eligibility Law
- Quest Can't Ditch TCPA Suit Over Debt Collection Call
- CMS Gets Backlash For Drug Prices In TV Ads Proposal
- Deals Rumor Mill: Taisho, Carlyle, Trilantic
- Unilever Wins Suit Over Safety Of St. Ives Face Scrub
- Judge Defends Decision Keeping Talc Cancer Case In Philly
- The Verdicts That Left A Mark In 2018
- Anthem Nabs Fees To Sanction Insys In $19M Fentanyl Fight
- Records In OxyContin Suit Are Public, Ky. Appeals Court Says
- Merck Tells High Court FDA OK In Rejecting Fosamax Warning
- Coming Soon: FDA Over-The-Counter Drug Approval Overhaul
- Judging A Book: Mills Reviews 'Mississippi's Federal Courts'
- The NantKwest Saga: Do Gov't Expenses Include Attys' Fees?
- MVP: Sullivan & Cromwell's Matt Hurd
- $50M Released Early For 2nd-Priority Dow Implant Victims
- Feds Fight To Keep Insys Grand Jury Instructions Secret
- EpiPen MDL Attys Scolded For 'Mindless Bickering'
- Covington & Burling Steers Merck's €2B Animal Tech Biz Buy
- AstraZeneca Sues Again Over Breast Cancer Drug Patents
- Abbott Labs Wants Atty DQ'd In Worker's Gender Bias Case
- Texas Justices Won't Hear Ranbaxy's Patent Arbitration Row
- 11th Circ. Affirms Scientists' $10.5M Fraud Convictions
- Fed. Circ. Rejects Atty Fee Bid In Surgical Tool IP Suit
- Sanofi Fires Back Against Mylan In Its Bid To Exit EpiPen MDL
- Fed. Circ. Reins In Reach Of Double-Patenting Doctrine
- The 6 Biggest Law Firm Mergers Of 2018
- Judge Fed Up With 'Whiny' Letters In Least Favorite Case
- MVP: Kirkland's Jay Lefkowitz
- The Subtle Art Of Fred Fielding
- Biotech Co. On Hook For $3.6M Int'l Arb. Judgment, Court Told
- MiMedx Dodges Rival's $6.8M Trade Secret, Breach Suit
- Biotech Biz Zymergen Lands $400M Series C Funding
- UT Can't Be Forced Into Patent Case, Ending Cancer IP Row
- PTAB Axes 2 Patents On Insulin Drug Lantus
- Hatch Introduces Bill To Restrict Generics' PTAB Challenges
- 6 Things That Rocked The Legal Industry In 2018
- Merck Loses Zoning Challenge Against Jersey Township
- Direct Buyers Win Cert. In Lamictal Antitrust Suit
- FDA Nixes Proposed Rule On Generic-Drug Warning Labels
- Top Product Liability Cases Of 2018
- MVP: Hogan Lovells' Adam Golden
- Insys Slams BCBS Privilege Claim In $19M Fentanyl Suit
- 5 Of 6 NECC Defendants Guilty In Latest Trial
- How Life Sciences Cos. Can Prepare For Legal And PR Crises
- Protecting Innovation While Justices Ponder Helsinn V. Teva
- FDA Explains Expectations For Drugmakers' Data Retention
- 8th Circ. Won't Revive Express Scripts Breach, Antitrust Suit
- Boston Scientific Wins $35M Verdict In Heart Valve Patent Suit
- IMMC Trustee Wants 3rd Circ. Redo In Ch. 11 Transfer Fight
- FDA Boss Vows Crackdown On Stem Cell, Supplement Cos.
- 1-800 Contacts Asks FTC To Stay Ruling Axing Ad Compacts
- Fed. Circ. OKs Teva's Patent Win Over Allergan Colitis Drug
- EU Court Slashes €100M From Servier Pay-For-Delay Fine
- Synergy Pharma Files Ch. 11, Bausch Health Offers $200M Bid
- 'Bundle' Buys Don't Avert FCA Liability, Feds Say In Bayer Suit
- Ex-Biotech Exec Avoids Prison For Lying To SEC
- MVP: Greenberg Traurig's Lori Cohen
- 10 Tips For Law Firms To Drive Revenue Via Sports Tickets
- Inside Key ABA Guidance On Attorneys' Cybersecurity Duties
- Revising FDA 510(k) Poses Challenges For Device Makers
- Amgen's Biosimilar IP Win Was Wrong, Hospira Tells Fed. Circ.
- Fed. Circ. OKs Stryker's $254M IP Win After High Court Trip
- Dental Products Maker Expands IP War Against Rival At ITC
- Full Fed. Circ. Urged To Review Venue In Cialis Patent Fight
- Accountant Seeks No Prison Time For $18M Tax Return Fraud
- ImmunoCellular Investors Seek OK Of $1.1M Stock Hype Deal
- Hoffman La-Roche Can't Keep Malaria Drug Suit In Fed. Court
- GNC Investors Can't Revive Securities Suit In 3rd Circ.
- Fed. Circ. Provides Clarity On Patent Term Questions
- 3rd Circ. Questions 'Imminent' Shire Antitrust Actions
- Endo Must Face Stock-Drop Claims In Opioid Safety Suit
- Texas Medical Device Co., Atty End Suit Over Alleged Scam
- Opening Comments: A Key Strategic Decision In Mediation
- MVP: Fish & Richardson's Jonathan Singer
- Shire Must Cough Up Some Docs In Pay-For-Delay Suit
- Judge Mulls Several Outcomes For NY Opioid Surcharge Law
- SEC Slams Man's 'Unfocused' Bid To Nix $11.5M Fraud Suit
- Fed. Circ. Upholds PTAB's Axing Of Inventory Tech Patent
- Keryx Investor Sues In Chancery For Akebia Merger Records
- FDA Hit With Suit Over Reporting Leeway For Clinical Trials
- J&J To Face Bulk Of Buyers' Claims In Remicade Antitrust Suit
- Olympus Pleads Guilty, Fined $85M In Tainted Scope Suits
- Medical Device Exec Beats Charges Of Tipping Orioles Player
- BioChemics Receiver Taps Sunstein, Nields For IP Work
- Tardy Claim Dooms $100M Biotech IP Suit In Chancery
- Pharmas Say FTC Pushing Subpoena Limits In AndroGel Row
- Stradling Nabs Ex-Sheppard Mullin M&A Partner
- Proposed FDA Drug Software Rules Strict On Pharma Cos.
- Post-Teva Expert Disclosure Trends In 2 Patent-Rich Districts
- More State Issues The Blue Wave May Shape In 2019
- Why The High Court Will Hear Cochise Consultancy V. US
- 2 Firms Nab Lead In 'Channel-Stuffing' Derivative Suits
- Fed. Circ. Revives Medical Device Co. Laerdal's ITC Case
- Fed. Circ. Reverses Ax Of Novartis Patent Due To 1995 Law
- J&J Can't Escape Retailers' Antitrust Suit Over Remicade
- Impax Says Investors' Drug Price-Fixing Suit Still Fails
- Genentech Asks Del. Chancery To Toss Takeda Patent Fight
- Fed. Circ. Upholds Patent On Novartis MS Drug
- Merck, Glenmark Can't Shake Zetia Pay-For-Delay MDL
- Medical Device Co. Can't Duck Philly Mass Tort Jurisdiction
- Health Hires: Hooper Lundy, King & Spalding, Williams Mullen
- Synergy Pharma Looks To Ditch Suit Over Side Effects, Loan
- Cook Medical Slashes 3rd Bellwether Suit In Vein Filter MDL
- Data-Driven Lawyer: Morgan Lewis' J. Kyle Poe
- Moderna Leads IPO Pair Raising $735M
- A Firsthand Account Of The Helsinn V. Teva Arguments
- Del. Justices Uphold Fresenius' $4.3B Akorn Merger Drop
- Trump Picks Kirkland's William Barr For AG
- JPMorgan, IV Debate The Meaning Of 'And' At Fed. Circ.
- Sherman Act Cut From Clot Drug Suit, State Claims Survive
- Genocea Beats Investor Claims It Hid Truth About Herpes Drug
- Dallas Paper Asks State Justices To Toss Defamation Claim
- Feds Blocked Again From Deposing Israelis In $163M Tax Row
- Mass. Priest Can't Escape SEC's Short-Selling Suit
- Gov't Presses Judge To Force Insys Founder To Produce Docs
- Amgen Settles 12th Sensipar Patent Fight
- Fed. Circ. Questions Allergan On Water's Role In Colitis Patent
- 'Opioid Babies' Denied MDL Separate From Ohio Gov't Suits
- Fed. Circ. Asks Whether Endo's Opioid Patent Was Obvious
- Actelion To Pay $360M To Resolve Copay Kickback Claims
- Data-Driven Lawyer: Ogletree's Evan Moses
- It's Harder To Withdraw From MDLs — For Good Reason
- Sens. Set Meeting To Talk Revamp Of Patent Eligibility Law
- Shire, Takeda Shareholders Give All Clear To £46B Deal
- Texas Says Opioid MDL Won't Let It Stop Deceptive Marketing
- Consumer Class Certified In Contact Lens Price-Fix Row
- Doctors Without Borders Seeks To Undo Gilead Hep C Patent
- Fresenius Hits Akorn 'Disaster' In $4B Del. Merger Appeal
- Kirkland Taps Allen & Overy Atty To Lead New IP Group In UK
- Medtronic To Pay Over $50M To Settle Medical Device Claims
- Data-Driven Lawyer: Kilpatrick Townsend's Kate Gaudry
- Drug Design Defect Litigation Faces Its Demise
- Aralez Ch. 11 Sale Problems Put Case On Path To Mediation
- Tax Court Judge Presses IRS On Mylan Legal Fee Deduction
- Justices Ask Tough Questions In AIA On-Sale Bar Case
- FTC Supports FDA's Plan To Curb Sham Petitioning
- 5 Key Questions As DOJ Torpedoes Gilead FCA Suit
- J&J Tells Fed. Circ. Judge Was Wrong To Nix Zytiga Patent
- Tribes Can't Seek Info On Fed Contracts, IHS In Opioid MDL
- Fed. Circ. Questions How Aventis Cancer Drug Is Inventive
- FDA Issues Proposed Rule For Novel Medical Devices
- 11th Circ. Revives Suit Over Protein Powder Labels
- Pa. Panel Questions Latest Bid To Ax Out-Of-State Mesh Suits
- Fed. Circ. Reluctant To Void CBM Review Of Inventory Patent
- Deals Rumor Mill: Daimler, Ardian, Grail
- Data-Driven Lawyer: Littler's Scott Forman
- Shook Hardy Kicked Off Monster Energy False-Ad Suit
- Property And Casualty Insurers Face A Genomics Revolution
- Antitrust Risk In Agreements Restricting Online Advertising
- Calif. Jury Clears Alere In Bio Test Cup Patent Suit
- Trump Admin. Urges Broad Easing Of Health Laws
- Atty Fighting Sanctions Says Lies Ignored In Insys Case
- Investor Flags Antibiotics Co. Melinta's $75M Stock Sale
- Aralez, Proposed Buyer Pan Creditors' Ch. 11 Sale Challenge
- Fla. Judge Recommends Trimming Pharmacy FCA Suit
- 2 Firms Lead Nov. IPO Action Fueled By Blank Check Cos.
- Novan Can Duck Claims It Misled Investors, Magistrate Says
- Former Walmart Pharmacist Says Race Played Role In Firing
- AIA On-Sale Bar At The High Court: What You Need To Know
- Walmart, 3 Pharma Cos. Sued Over Tainted Combo Drug
- EpiPen Maker Slams Sanofi's Bid To Exit Antitrust MDL
- Fed. Circ. Wary Of Zimmer Call To Cut Stryker Patent Award
- Pharma Co. Egalet's Ch. 11 Statement OK'd In Del.
- A Chance For High Court To Clarify On-Sale Bar
- Judging A Book: Ginsburg Reviews 'The Curse Of Bigness'
- High Court OKs SG To Argue In Merck's Fosamax Appeal
- J&J Led By Profits To Push Allegedly Faulty Mesh, Jury Told
- 5 Things You Should Know About New Rule 23 Amendments
- Data-Driven Lawyer: DLA Piper's Eric Falkenberry
- 7 Firms Steer GSK's £3B India Unit Sale, $5B Oncology Buy
- The Data-Driven Lawyers Of 2018